Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.
Kevin BiglanLeanne MunsieKjell A SvenssonPaul ArdayfioMelissa PughJohn SimsMiroslaw BrysPublished in: Movement disorders : official journal of the Movement Disorder Society (2021)
Mevidalen harnesses a novel mechanism of action that improves motor symptoms associated with LBD on top of standard of care while improving or not worsening non-motor symptoms associated with traditional dopaminergic therapy. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Keyphrases
- double blind
- placebo controlled
- healthcare
- mild cognitive impairment
- open label
- palliative care
- sleep quality
- clinical trial
- quality improvement
- cognitive impairment
- phase iii
- parkinson disease
- phase ii
- study protocol
- systematic review
- randomized controlled trial
- depressive symptoms
- cell therapy
- mesenchymal stem cells
- meta analyses